NASDAQ : STOK
Stoke Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 26.29 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.70B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.72B |
| Enterprise Value | 1.36B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 64.81M |
| Shares Outstanding | 64.81M |
| Shares Change (YoY) | +8.94% |
| Shares Change (QoQ) | +3.55% |
| Owned by Insiders (%) | 3.70% |
| Owned by Institutions (%) | 95.10% |
| Float | 45.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 60.84 |
| Forward PS | 51.93 |
| PB Ratio | 4.87 |
| P/TBV Ratio | 4.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 48.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.24 |
| Quick Ratio | 6.72 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28,622.33 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -73.62% |
| Return on Assets (ROA) | -41.98% |
| Return on Invested Capital (ROIC) | -575.69% |
| Return on Capital Employed (ROCE) | -72.01% |
| Weighted Average Cost of Capital (WACC) | 11.19% |
| Revenue Per Employee | $165,941 |
| Profits Per Employee | -$1.43M |
| Employee Count | 170 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -11.85% |
| 50-Day Moving Average | 27.31 |
| 200-Day Moving Average | 30.90 |
| Relative Strength Index (RSI) | 53.48 |
| Average Volume (20 Days) | 1,272,784 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.26M |
| Short Previous Month | 11.51M |
| Short % of Shares Out | 15.83% |
| Short % of Float | 22.35% |
| Short Ratio (days to cover) | 10.28 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 28.21M |
| Gross Profit | 28.21M |
| Operating Income | -257.60M |
| Pretax Income | -243.20M |
| Net Income | -243.20M |
| EBITDA | -255.82M |
| EBIT | -257.60M |
| Loss Per Share | -$3.75 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 319.19M |
| Total Debt | 681,000 |
| Net Cash | 358.11M |
| Net Cash Per Share | $5.53 |
| Equity (Book Value) | 352.59M |
| Book Value Per Share | 5.44 |
| Working Capital | 305.44M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -177.99M |
| Capital Expenditures | -2.69M |
| Depreciation & Amortization | 1.78M |
| Net Borrowing | n/a |
| Free Cash Flow | -180.68M |
| FCF Per Share | -$2.79 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -913.15% |
| Pretax Margin | -862.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.94% |
| Shareholder Yield | -8.94% |
| Earnings Yield | -14.16% |
| FCF Yield | -10.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $46.38 |
| Price Target Difference | 75.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | -10.75% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 17.25 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |